Healthcare / Drug Manufacturers - Specialty & GenericShenzhen
$6.87
+0.18 (+2.69%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $141.5M · quality 77.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
54/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.5B
P/E
15.3x
↓EV/EBITDA
11.6x
↓ROE
8.3%
↑Gross Margin
77.4%
↑Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+4.3%
FCF CAGR
+21.0%
FCF margin
22.6%
FCF / Net income
1.18x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.04B · net income $198.1M · FCF $234.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.04B | $1.04B | $1.00B | $955.5M | $916.1M |
| Net Income | $198.1M | $198.1M | $220.2M | $205.0M | $167.6M |
| EBITDA | $281.0M | $281.0M | $296.1M | $280.7M | $237.3M |
| EPS | 0.39 | 0.39 | 0.44 | 0.41 | 0.33 |
| Gross Margin | 77.4% | 77.4% | 75.9% | 73.2% | 72.1% |
| Operating Margin | 23.3% | 23.3% | 24.1% | 18.6% | 15.3% |
| Net Margin | 19.1% | 19.1% | 21.9% | 21.5% | 18.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.02 | 0.02 | 0.04 | 0.05 | 0.06 |
| Current Ratio | 4.49 | 4.49 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $234.3M | $234.3M | $119.1M | $141.5M | $132.3M |
| Returns | |||||
| ROE | 8.3% | 8.3% | 10.0% | 10.4% | 8.8% |
| Valuation | |||||
| P/E | 15.27 | 15.27 | 13.07 | 16.86 | 18.25 |
| EV/EBITDA | 11.62 | 11.62 | 9.57 | 12.47 | 12.78 |
| P/B | 1.45 | 1.45 | 1.31 | 1.76 | 1.62 |
| Growth & Yield | |||||
| Revenue Growth | 3.4% | 3.4% | 5.1% | 4.3% | — |
| EPS Growth | -10.1% | -10.1% | 7.4% | 22.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
15.7%
EPS terminal req.
$0.61
Spread vs growth
-25.7%
5Y implied EPS CAGR
13.4%
EPS terminal req.
$0.74
Spread vs growth
-23.4%
10Y implied EPS CAGR
11.7%
EPS terminal req.
$1.19
Spread vs growth
-21.7%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+18.4%
Start / end P/E
13.3x → 17.4x
EPS bridge
0.44 → 0.39
Residual
-3.2%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.